CN110974962B - 肿瘤免疫凝胶制剂的合成方法 - Google Patents
肿瘤免疫凝胶制剂的合成方法 Download PDFInfo
- Publication number
- CN110974962B CN110974962B CN201911330343.3A CN201911330343A CN110974962B CN 110974962 B CN110974962 B CN 110974962B CN 201911330343 A CN201911330343 A CN 201911330343A CN 110974962 B CN110974962 B CN 110974962B
- Authority
- CN
- China
- Prior art keywords
- plga
- icg
- tumor
- peg
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000036039 immunity Effects 0.000 title claims abstract description 4
- 238000001308 synthesis method Methods 0.000 title claims description 4
- 229960004657 indocyanine green Drugs 0.000 claims abstract description 41
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims abstract description 31
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 claims abstract description 24
- 239000000243 solution Substances 0.000 claims abstract description 23
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 15
- 241000711408 Murine respirovirus Species 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 6
- 230000002194 synthesizing effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 238000002255 vaccination Methods 0.000 abstract description 2
- 230000028993 immune response Effects 0.000 abstract 1
- 230000006054 immunological memory Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公布一种肿瘤免疫凝胶制剂的合成方法。主要步骤包括:1)PLGA‑PEG‑PLGA凝胶溶液的制备；2)混合法制备SEV‑4I1@ICG肿瘤免疫凝胶。仙台病毒(SEV)可全身性激活机体免疫功能，形成肌体对肿瘤的免疫反应，并形成免疫记忆，对肿瘤杀伤和清除。吲哚菁绿(ICG)的荧光效应使疫苗接种的过程可视化，其产生的光热效应也可清除剩余的病毒及肿瘤细胞。PLGA‑PEG‑PLGA无毒，生物相容性好，在常温下呈液态，35度左右相变为凝胶，可以很好地用于体内注射，延长药物在体内的滞留，从而提高效果。这种病毒介导的肿瘤免疫凝胶可很好地预防肿瘤的产生。
Description
技术领域
本发明涉及免疫凝胶制剂制备方法，具体为一种通过PLGA-PEG-PLGA包裹仙台病毒(SEV)、吲哚菁绿(ICG)和4T1肿瘤细胞的策略,合成肿瘤免疫凝胶制剂的方法。
背景技术
目前，肿瘤是世界上对人类威胁最大的疾病之一。免疫治疗通过激活人体免疫系统，依靠自身免疫机能杀灭癌细胞和肿瘤组织，从而达到治疗癌症的作用。鉴于灭活的仙台病毒(SEV)可以作为异物在体内可以激发全身免疫系统产生细胞因子风暴(如干扰素、肿瘤坏死因子和各种白细胞介素等)，并使在抗肿瘤治疗过程中具有重要作用的树突状细胞(DC细胞，提呈肿瘤抗原)，巨噬细胞(细胞，吞噬肿瘤细胞)和自然杀伤细胞(NK细胞，杀伤肿瘤细胞)等被大量激活，随后大幅提高T细胞的增值效率。这种基于仙台病毒的免疫凝胶通过激活患者自身免疫系统，利用肿瘤细胞或肿瘤抗原物质诱导机体的特异性细胞免疫和体液免疫反应，增强机体的抗癌能力，阻止肿瘤的生长、扩散和复发，以达到清除或控制肿瘤的目的。
ICG化学名为吲哚菁绿，是一种感光染料，是美国食品药品监督管理局(FDA)惟一批准的体内应用染料。它注入血液后会迅速与清蛋白及α1-脂蛋白结合(98％)，随血液经过肝脏时，90％以上被肝细胞摄取，再以原形由胆道排泄，不参与体内化学反应，无肠肝循环，无淋巴逆流，不从肾脏等肝外脏器排泄，无辐射，无毒副作用。
PLGA-PEG-PLGA是一种三嵌段聚合物。其中PLGA由两种单体——乳酸和羟基乙酸随机聚合而成，是一种可降解的功能高分子有机化合物，其降解产物是乳酸和羟基乙酸，同时也是人代谢途径的副产物，所当它应用在医药和生物材料中时不会有毒副作用，具有良好的生物相容性、无毒、良好的成囊和成膜的性能。PEG具有良好的水溶性，生物相容性好，并赋予了聚合物温敏相变的性质。
发明内容
本发明为克服现有技术的不足，提供一种通过PLGA-PEG-PLGA包裹仙台病毒(SEV)、吲哚菁绿(ICG)和4T1肿瘤细胞的策略,合成肿瘤免疫凝胶制剂的方法。利用肿瘤细胞或肿瘤抗原物质诱导机体的特异性细胞免疫和体液免疫反应，增强机体的抗癌能力，阻止肿瘤的生长、扩散和复发，以达到清除或控制肿瘤的目的。
本发明的技术方案是一种肿瘤免疫凝胶制剂的合成方法，通过PLGA-PEG-PLGA包裹仙台病毒(SEV)吲哚菁绿(ICG)和4T1肿瘤细胞的策略,具体步骤如下：
1)称取PLGA-PEG-PLGA材料，加入水中溶解，得到浓度为0.2-0.5mg/ml的PLGA溶液；
2)称取ICG材料，加入水中溶解，得到浓度为5-10mg/ml的ICG溶液；
3)各取适量混合成肿瘤免疫凝胶。
所述步骤3)具体如下：
(1)在室温下将盛有1ml的PLGA-PEG-PLGA溶液的单口瓶置于旋转搅拌器上，搅拌速度设定为500r/min；
(2)边搅拌边逐滴加入8uL的ICG水溶液和20uL4T1肿瘤细胞溶液和20uLSEV溶液，继续搅拌直至完全混匀，最终得到SEV-4I1@ICG免疫凝胶。
本发明的优势在于：
1)仙台病毒SEV可以激活细胞免疫,增强机体的抗癌能力，阻止肿瘤的生长、扩散和复发，以达到清除或控制肿瘤的目的。
2)吲哚菁绿(ICG)的荧光效应使疫苗接种的过程可视化，其产生的光热效应也可清除剩余的病毒及肿瘤细胞。
3)PLGA-PEG-PLGA无毒，生物相容性好，在常温下呈液态，35度左右相变为凝胶，可以很好地用于体内注射，延长药物在体内的滞留，从而提高效果。
附图说明
图1：PLGA-PEG-PLGA的1H NMR图。
图2：SEV-4I1@ICG免疫凝胶光热效应曲线图。
具体实施方式
以下结合附图和具体实施例来对本发明作进一步的说明。
实施例1：
1)准确称取0.25mg的PLGA-PEG-PLGA材料，加入1mL水溶解，得到浓度为0.25mg/ml的PLGA-PEG-PLGA水溶液。
2)准确称取5mg的ICG材料，加入1mL水溶解，得到浓度为5mg/ml的ICG水溶液。
3)混合法合成SEV-4I1@ICG免疫凝胶的方法如下：
(1)在室温下将盛有1ml的PLGA-PEG-PLGA溶液的单口瓶置于旋转搅拌器上，搅拌速度设定为500r/min；
(2)边搅拌边逐滴加入8uL的ICG水溶液和20uL4T1肿瘤细胞溶液和20uLSEV溶液，继续搅拌直至完全混匀，最终得到SEV-4I1@ICG免疫凝胶。
实施例2：
1)准确称取0.2mg的PLGA材料，加入1mL水溶解，得到浓度为0.2mg/ml的PLGA-PEG-PLGA水溶液。
2)准确称取8mg的ICG材料，加入1mL水溶解，得到浓度为8mg/ml的ICG水溶液。
3)混合法合成SEV-4I1@ICG免疫凝胶的方法如下：
(1)在室温下将盛有1ml的PLGA-PEG-PLGA溶液的单口瓶置于旋转搅拌器上，搅拌速度设定为500r/min；
(2)边搅拌边逐滴加入6uL的ICG水溶液和20uL4T1肿瘤细胞溶液和20uLSEV溶液，继续搅拌直至完全混匀，最终得到SEV-4I1@ICG免疫凝胶。
实施例3：
1)准确称取0.5mg的PLGA-PEG-PLGA材料，加入1mL水溶解，得到浓度为0.5mg/ml的PLGA-PEG-PLGA水溶液。
2)准确称取10mg的ICG材料，加入1mL水溶解，得到浓度为10mg/ml的ICG水溶液。
3)混合法合成SEV-4I1@ICG免疫凝胶的方法如下：
(1)在室温下将盛有1ml的PLGA-PEG-PLGA溶液的单口瓶置于旋转搅拌器上，搅拌速度设定为500r/min；
(2)边搅拌边逐滴加入10uL的ICG水溶液和20uL4T1肿瘤细胞溶液和20uLSEV溶液，继续搅拌直至完全混匀，最终得到SEV-4I1@ICG免疫凝胶。
Claims (1)
1.肿瘤免疫凝胶制剂的合成方法，其特征是，通过PLGA-PEG-PLGA包裹仙台病毒(SEV)、吲哚菁绿(ICG)和4T1肿瘤细胞的策略,具体步骤如下：
1)称取PLGA-PEG-PLGA材料，加入水中溶解，得到浓度为0.2-0.5mg/ml的PLGA-PEG-PLGA溶液；
2)称取ICG材料，加入水中溶解，得到浓度为5-10mg/ml的ICG溶液；
3)混合成肿瘤免疫凝胶；
所述步骤3)具体如下：(1)在室温下将盛有1ml的PLGA-PEG-PLGA溶液的单口瓶置于旋转搅拌器上，搅拌速度设定为500r/min；
(2)边搅拌边逐滴加入6-10uL的ICG水溶液和20uL4T1肿瘤细胞溶液和20uLSEV溶液，继续搅拌直至完全混匀，最终得到SEV-4I1@ICG免疫凝胶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911330343.3A CN110974962B (zh) | 2019-12-20 | 2019-12-20 | 肿瘤免疫凝胶制剂的合成方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911330343.3A CN110974962B (zh) | 2019-12-20 | 2019-12-20 | 肿瘤免疫凝胶制剂的合成方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110974962A CN110974962A (zh) | 2020-04-10 |
| CN110974962B true CN110974962B (zh) | 2022-08-30 |
Family
ID=70073916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911330343.3A Active CN110974962B (zh) | 2019-12-20 | 2019-12-20 | 肿瘤免疫凝胶制剂的合成方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110974962B (zh) |
-
2019
- 2019-12-20 CN CN201911330343.3A patent/CN110974962B/zh active Active
Non-Patent Citations (1)
| Title |
|---|
| "希罗达对4T1乳腺癌小鼠肿瘤血管生成的影响";杨芳等;《现代生物医学进展》;20071231;第7卷(第9期);第1294-1296页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110974962A (zh) | 2020-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu et al. | Responsive hydrogels based on triggered click reactions for liver cancer | |
| KR102083023B1 (ko) | 표면 기능화된 약물 운반 가능한 용출 마이크로스피어의 제조 방법 | |
| CN108186575B (zh) | 一种基于低共熔溶剂为溶剂的包埋体系 | |
| CN106693040A (zh) | 一种可载药聚乙烯醇洗脱微球的制备方法 | |
| CN110237264A (zh) | 一种包载盐酸阿霉素的TA-Fe(III)修饰的PLGA纳米颗粒及其制备方法 | |
| CN116509794B (zh) | 一种口服温敏凝胶制剂及其制备方法与应用 | |
| CN105859990B (zh) | 侧链含硫辛酰基的聚合物、其制备方法及由其制备的聚合物囊泡及其应用 | |
| TW200906437A (en) | Pasireotide formulation | |
| CN102091025A (zh) | 抗肿瘤可注射水凝胶及其制备方法和用途 | |
| Wang et al. | Construction of single-injection vaccine using new time-controlled release system | |
| CN111450252B (zh) | 一种用于靶向堵塞肿瘤血管的药物及其制备方法与应用 | |
| CN113876716B (zh) | 一种治疗胃肠道疾病的生物粘附性纳米粒及其制备方法 | |
| CN107837229A (zh) | 一种缓释阿霉素脂质体的温敏水凝胶制剂及制备方法 | |
| CN110974962B (zh) | 肿瘤免疫凝胶制剂的合成方法 | |
| CN106667958A (zh) | 一种多肽缓释微球制剂及其制备方法 | |
| CN109464676A (zh) | 一种壳寡糖光敏靶向纳米粒的制备方法及产品 | |
| Biswas et al. | Gel based formulations in oral controlled release drug delivery | |
| CN106474486B (zh) | 一种聚合物胶束及其应用 | |
| CN109481418A (zh) | 抗肿瘤纳米颗粒及其制备方法和应用 | |
| CN111514289A (zh) | 新冠病毒免疫纳米颗粒制剂的合成方法 | |
| CA2482929C (en) | Tuberculin immunoadjuvant | |
| TW201125575A (en) | Sustained-release formulation | |
| CN107737347A (zh) | 一种新型双靶向果胶‑多臂聚乙二醇联合抗癌药物的制备 | |
| CN111450047A (zh) | 一种mers病毒免疫凝胶制剂的合成方法 | |
| CN111450046A (zh) | 一种新冠病毒免疫凝胶制剂的合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |